Dr. Jeremie Calais honored for contributions to nuclear medicine and theranostics

Dr. Jeremie Calais
Dr. Jeremie Calais

Dr. Jeremie Calais, adjunct professor at UCLA and an internationally recognized leader in nuclear medicine and theranostics, was selected by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to deliver the Dr. Sanjiv “Sam” Gambhir Annual Lecture in Nuclear Medicine Treatments and Diagnostics in recognition of his contributions to advancing cancer imaging and targeted therapies.

The prestigious lectureship honors leaders whose research advances early disease detection, precision medicine and personalized treatment.

“Dr. Gambhir’s vision of detecting disease earlier and developing more precise, personalized treatments has had a profound influence on our field,” said Calais. “It is a tremendous honor to receive this recognition and an opportunity to reflect on how far we have come in theranostics and the possibilities that lie ahead.” 

Calais helped advance the use of molecular imaging and targeted radiopharmaceutical therapies for people with cancer. His research contributed to the first U.S. Food and Drug Administration approval of a prostate-specific membrane antigen (PSMA) PET imaging agent in 2020 and helped establish radioligand therapy as a treatment option for people with advanced prostate cancer. He also directed UCLA’s Theranostics Clinical Research Program, co-led the opening of its dedicated theranostics treatment center and helped establish the nation’s first independent Department of Nuclear Medicine and Theranostics.

Book An Appointment

See a doctor, virtually or in-person, with our easy online booking options.

Related Content

Cancer Center Member

Media Contact

Denise Heady
310-948-3691
[email protected]